# PRESS RELEASE 2022

# [Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer](/content/ferring-receives-approval-from-u-s-fda-for-adstiladrin-for-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 16 December 2022

Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle...

# [Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A novel first-in-class microbiota-based live biotherapeutic](/content/ferring-receives-u-s-fda-approval-for-rebyota-fecal-microbiota-live-jslm-a-novel-first-in-class-microbiota-based-live-biotherapeutic/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 30 November 2022

Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A...

# [Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)](/content/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 15 November 2022

…

# [Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs](/content/pivotal-phase-3-efficacy-and-safety-data-for-ferrings-rbx2660-published-in-drugs/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 07 November 2022

Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in...

# [Ferring Pharmaceuticals and Blackstone Life Sciences restructure novel gene therapy collaboration](/content/ferring-pharmaceuticals-and-blackstone-life-sciences-restructure-novel-gene-therapy-collaboration/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 17 October 2022

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted...

# [Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660](/content/ferring-receives-positive-vote-from-u-s-fda-advisory-committee-for-rbx2660/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 22 September 2022

# [Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic](/content/ferring-announces-u-s-fda-advisory-committee-meeting-for-rbx2660-its-investigational-microbiota-based-live-biotherapeutic/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 09 August 2022

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) will hold a meeting on September 22, 2022...

# [Ferring announces ground-breaking and inclusive family building benefits package for all its employees globally](/content/ferring-announce-ground-breaking-and-inclusive-family-building-benefits-package-for-all-its-employees-globally/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 14 July 2022

Ferring Pharmaceuticals is committed to building families of every shape and size. As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees...

# [Ferring Announces New Collaboration for Development of Olamkicept](/content/ferring-announces-new-collaboration-for-development-of-olamkicept/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 09 June 2022

Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions...

# [Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic](/content/ferring-presents-new-analyses-of-efficacy-safety-and-microbiome-composition-data-at-ddw-2022-for-rbx2660-its-investigational-microbiota-based-live-biotherapeutic/index.html)

By [celia](/content/author/celia/index.html) in [PRESS RELEASE 2022](/content/category/press-release-2022/index.html) on 24 May 2022

New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660.